Tumor family history, treatment level, lymph node metastasis, EGFR mutation type, and EGFR mutation immune score combined several EGFR groups, but both groups were mostly female, nonsmoking, ≥60 years old, and leukemia patients. This evidence concerns the gene EGFR and metastatic malignant neoplasm in the lymph nodes.